Aspart flexpen insulin refers to insulin aspart, a rapid-acting insulin analog, delivered via a pre-filled injection pen known as a FlexPen. This combination is used to manage blood sugar levels in individuals with diabetes.
How does insulin aspart work in a FlexPen?
Insulin aspart works by lowering blood glucose levels. It is absorbed quickly into the bloodstream and begins to lower glucose within 10-20 minutes after injection, with its peak activity occurring between 1 to 2 hours. The duration of action is approximately 3 to 5 hours [1]. The FlexPen is a disposable insulin delivery device that allows for easy and accurate dosing of the insulin aspart.
What types of diabetes is insulin aspart FlexPen used for?
Insulin aspart FlexPen is indicated for the treatment of diabetes mellitus in adults and children aged 2 years and older. It is used to improve glycemic control [1]. It is often used to manage blood sugar levels around meal times.
What are the brand names for insulin aspart FlexPen?
Insulin aspart FlexPen is marketed under several brand names. In the United States, it is primarily known as NovoLog FlexPen and NovoLog Mix 70/30 FlexPen, which is a combination of insulin aspart protamine and insulin aspart. Other international brand names include NovoRapid FlexPen [2].
When does the patent for NovoLog FlexPen expire?
The patent landscape for branded medications can be complex, involving multiple patents covering the drug substance, formulation, and delivery device. For NovoLog FlexPen (insulin aspart), primary patents have expired or are set to expire. According to DrugPatentWatch.com, the key patents covering insulin aspart have largely expired, paving the way for generic competition [3]. Specific patent expiry dates can vary due to different patent types and any subsequent litigation or extensions.
Can generic versions of insulin aspart FlexPen be produced?
With the expiry of key patents, generic versions of insulin aspart can be developed and marketed. These generic products are intended to be bioequivalent to the branded version, offering a more affordable treatment option for patients [3]. The availability of generics depends on regulatory approvals in different markets.
What is the difference between insulin aspart and other rapid-acting insulins?
Insulin aspart is a rapid-acting insulin analog. Compared to regular human insulin, insulin aspart has a faster onset of action and a shorter duration of effect, making it more suitable for mealtime glucose control. Other rapid-acting insulins include insulin lispro and insulin glulisine, which share similar pharmacokinetic profiles and are also used for prandial glucose management [1].
What are the potential side effects of insulin aspart FlexPen?
The most common side effect of insulin aspart FlexPen, like all insulins, is hypoglycemia (low blood sugar). Other potential side effects include allergic reactions, changes in lipodystrophy at injection sites, and weight gain. Patients should be educated on recognizing and managing hypoglycemia [1].
How should insulin aspart FlexPen be stored?
Unused insulin aspart FlexPen should be stored in a refrigerator at 36°F to 46°F (2°C to 8°C). Once a FlexPen is in use, it can be kept at room temperature, below 86°F (30°C), for up to 28 days. It should be protected from heat and light and not frozen [1].
Where can I find more information on insulin aspart patents?
Information regarding patents for insulin aspart and its delivery devices can be found through patent databases and specialized intellectual property tracking services. DrugPatentWatch.com provides detailed patent information, including expiry dates and legal challenges, for various pharmaceuticals, including insulin aspart [3].
---
Sources:
[1] Novo Nordisk Inc. NovoLog® (insulin aspart [rDNA origin]) injection, NovoLog FlexPen® (insulin aspart [rDNA origin]) injection. Prescribing Information.
[2] DrugPatentWatch.com
[3] DrugPatentWatch.com